Stock listing
OTC:HDII Hypertension Diagnostics, Inc. Stock
Follow Hypertension Diagnostics, Inc. into a list and get an email when it puts out news.
- Ticker
- OTC:HDII
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Hypertension Diagnostics, Inc. on 6ix
- News releases
- 4 in all · newest Apr 22, 2021 · oldest 2020
Events
| Quarter | Results |
|---|
| Quarter to Dec 31, 2024 | Feb 21, 2025 |
|---|
| Quarter to Sep 30, 2024 | Nov 18, 2024 |
|---|
| Quarter to Jun 30, 2024 | Aug 28, 2024 |
|---|
| Quarter to Mar 31, 2024 | May 22, 2024 |
|---|
| Quarter to Dec 31, 2023 | Feb 16, 2024 |
|---|
| Q3 2023 | Nov 3, 2023 |
|---|
| Q2 2023 | Aug 30, 2023 |
|---|
| Q1 2023 | May 17, 2023 |
|---|
| Q4 2022 | Feb 17, 2023 |
|---|
| Q3 2022 | Nov 4, 2022 |
|---|
All 17 quarters
| Quarter | Results |
|---|
| Q2 2022 | Aug 31, 2022 |
|---|
| Q1 2022 | May 18, 2022 |
|---|
| Q4 2021 | Feb 18, 2022 |
|---|
| Q3 2021 | Nov 5, 2021 |
|---|
| Q2 2021 | Sep 1, 2021 |
|---|
| Q1 2021 | May 19, 2021 |
|---|
| Q4 2020 | Feb 19, 2021 |
|---|
Open Events
Financials
Annual, in USD
Income statement
| Line | FY2022 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 | FY2017 | FY2016 | FY2012 |
|---|
| Revenue | | | | | | | 3.79M | 3.68M | 3.57M | 3.16M |
|---|
| Cost of revenue | | | | | | | 2.84M | 2.93M | 3.02M | 3.27M |
|---|
| Gross profit | | | | | | | 954.5K | 752.4K | 551.2K | -112.0K |
|---|
| Selling, general and administrative | | | | | | | | 917.8K | 1.02M | 1.19M |
|---|
| Operating income | | -121.9K | -121.9K | -11.0K | -11.0K | -420.0K | -420.0K | -403.5K | -656.0K | -1.36M |
|---|
| Depreciation and amortization | 167.9K | | 228.5K | | 236.6K | | 36.0K | 31.3K | 34.8K | 107.2K |
|---|
| EBITDA | | | 106.6K | | 225.6K | | -384.0K | -372.2K | -621.2K | -1.25M |
|---|
| Interest expense | | | | | | | 161.7K | 158.5K | 155.4K | 143.6K |
|---|
| Income before tax | | -93.2K | -93.2K | -11.0K | -11.0K | 3.29M | 3.29M | -368.6K | -622.0K | -1.47M |
|---|
| Income tax | | | -228.0K | | -237.0K | | -206.0K | 166.6K | 163.3K | -65.5K |
|---|
| Net income | | -93.2K | -93.2K | -11.0K | -11.0K | 3.29M | 3.29M | -368.6K | -622.0K | -1.14M |
|---|
| Earnings per share, basic | | -0.00 | -0.00 | -0.00 | -0.00 | 0.02 | 0.02 | -0.00 | -0.01 | -0.02 |
|---|
Balance sheet
| Line | FY2022 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 | FY2017 | FY2016 | FY2012 |
|---|
| Cash and equivalents | | | | 86.4K | 86.4K | 86.4K | 86.4K | 285.4K | 190.2K | 75.0K |
|---|
| Receivables | | | | 191.8K | 191.8K | 191.8K | 191.8K | 371.2K | 177.3K | 297.9K |
|---|
| Inventory | | | | 189.4K | 189.4K | 189.4K | 189.4K | 186.5K | 183.6K | 172.2K |
|---|
| Current assets | | | | 509.6K | 509.6K | 509.6K | 509.6K | 883.1K | 767.0K | 576.4K |
|---|
| Property, plant and equipment | | | | | | | | 509.5K | 576.8K | 678.3K |
|---|
| Total assets | | | | 1.08M | 1.08M | 1.08M | 1.08M | 1.49M | 1.40M | 1.31M |
|---|
| Accounts payable | | | | 445.6K | 445.6K | 445.6K | 445.6K | 422.1K | 400.2K | 170.8K |
|---|
| Current liabilities | | 121.9K | 121.9K | 1.34M | 1.34M | 1.34M | 1.34M | 1.69M | 1.46M | 654.8K |
|---|
| Long-term debt | | | | | | | | 4.69M | 4.20M | 610.6K |
|---|
| Total debt | | | | 651.3K | 651.3K | 775.0K | 775.0K | 4.42M | 4.20M | 610.6K |
|---|
| Total liabilities | | 121.9K | 121.9K | 2.00M | 2.00M | 2.12M | 2.12M | 6.12M | 5.66M | 1.59M |
|---|
| Shareholders' equity | | | -121.9K | -913.7K | -913.7K | -1.04M | -1.04M | -4.63M | -4.26M | -288.7K |
|---|
| Shares outstanding | 284.8M | 213.1M | 213.1M | 149.2M | 149.2M | 136.8M | 136.8M | 93.3M | 52.4M | 54.2M |
|---|
Cash flow
| Line | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 | FY2017 | FY2016 | FY2012 |
|---|
| Cash from operations | -892.3K | -892.3K | -11.0K | -11.0K | 3.49M | 3.49M | -85.9K | -384.9K | -1.23M |
|---|
| Capital spending | 0 | -3 | 0 | 0 | 0 | -2.11K | -2.03K | -1.96K | -630.5K |
|---|
| Free cash flow | -892.3K | -892.3K | -11.0K | -11.0K | 3.49M | 3.49M | -88.0K | -386.9K | -1.86M |
|---|
| Cash from investing | | 572.1K | | | | -2.11K | -2.11K | -1.96K | -380.5K |
|---|
| Cash from financing | 233.7K | 233.7K | 11.0K | 11.0K | -3.49M | -3.49M | 183.2K | 263.8K | 927.3K |
|---|
| Change in cash | -86.4K | -86.4K | | | | -202.0K | 95.2K | -123.1K | -678.8K |
|---|
Open Financials
Cap table
Built by 6ix from Hypertension Diagnostics, Inc.’s releases
- Common shares
- 284,781,623
- Fully diluted
- 284,781,623
Fully diluted
| Line | Shares |
|---|
| Common shares | 284,781,623 |
|---|
Share count over time
| Count | Shares |
|---|
| Nov 22, 2026 | 284,781,623 |
|---|
Open Cap table
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|
| Mark N. Schwartz | Chief Executive Officer, Director · Feb 28, 2006 – Mar 31, 2006 · Past |
|---|
Open People
Log in to ask 6ix AI your own questions about Hypertension Diagnostics, Inc.